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I. Executive Summary   
Persons with life-limiting illness who are nearing the end of life need to know that they will be 
cared for with compassion and dignity, and that their preferences for medical treatment will be 
honored.  Yet even when patients are well informed about care options, their goals of care are 
not always met.  While some patients may undergo more intensive medical interventions than 
they want, others may receive less.  This discrepancy between what patients want and what 
they receive often results from inadequate communication among the patient, the family and 
the health care provider.  Recent initiatives such as the National Priorities Partnership, 
convened by the National Quality Forum, have acknowledged this issue by identifying effective 
communication about treatment options as an important element of compassionate care. 
In Massachusetts there is no standardized way for patients to express life-sustaining treatment 
preferences in a way that can be readily understood and followed by members of the health 
care team in all settings of care.  To address these concerns, the Massachusetts Legislature 
mandated the Medical Orders for Life-Sustaining Treatment (MOLST) Demonstration Program 
in 2008. To that end, a Steering Committee was charged with planning, designing and 
demonstrating how MOLST could be implemented in one region of the Commonwealth.  Nine 
implementation sites across the continuum of care were recruited in the Worcester area. 
MOLST is a process and a standardized form used to translate life-sustaining treatment 
preferences into valid medical orders that can be honored across all healthcare settings.  
MOLST is a tool clinicians may use to document patient preferences about life-sustaining 
treatment after thoroughly discussing with patients their medical condition, prognosis, the 
potential burdens and benefits of any recommended treatments, and the patient’s values and 
goals of care.  MOLST is intended for patients of any age who are nearing the end of life with a 
serious advancing medical condition, including (but not limited to) life-threatening disease or 
injury, chronic progressive disease and/or medical frailty.  MOLST use is voluntary and the 
MOLST form may indicate that the patient requests or 
Based on the national paradigm POLST, or Physician’s Orders for Life-Sustaining Treatment, the 
Massachusetts MOLST form was modified after interviews with scores of health care 
professionals and diverse consumer groups in the Commonwealth.  Input from a broad array of 
participants, both professional and consumer, was also solicited and incorporated into the 
development of the MOLST process and other MOLST materials.   
refuses certain treatments.  MOLST is 
not intended for routine use with patients who have early stage or stable medical conditions. 
Clinicians began using the MOLST form in the demonstration sites on April 1, 2010.  Local site 
champions promoted use of the form and process.  Health care professionals at the sites and in 
the surrounding communities participated in MOLST training and informational sessions. The 
demonstration provided the opportunity to test the process of implementation, to identify 
facilitators and barriers in MOLST utilization, and to uncover other related issues. 
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Chief among the findings in the demonstration program was that MOLST was seen as an 
improvement over existing tools for documenting preferences for care near the end of life. 
Consumer groups identified MOLST as a tool that could greatly benefit patients and families.  
Clinicians welcomed the MOLST form as a document that is easy to use, well-organized, and 
adaptable for different settings. Strong support emerged from not only the demonstration sites 
but also from numerous other interested individuals and organizations. 
As a result of the overwhelmingly positive findings from the MOLST Demonstration Program, 
the MOLST Steering Committee holds the vision that in Massachusetts:  
1. Every suitable patient will be offered the opportunity to utilize a MOLST form in concert 
with that patient’s clinician to communicate life sustaining treatment preferences across 
health care settings.  
2. Every emergency medical technician will receive MOLST training and be authorized to 
honor valid MOLST forms.  
3. Every major hospital system and health care plan will implement policies and procedures 
to facilitate the appropriate utilization of MOLST by clinicians and patients.  
4. Every clinician will seek to improve communications skills with patients nearing the end 
of life; have access to MOLST education; and be encouraged by professional 
organizations and regulatory bodies (e.g. Boards of Registration, Massachusetts Medical 
Society) to utilize MOLST correctly.  
5. MOLST forms as well as education and outreach materials will be uniform; linguistically 
appropriate; culturally relevant; easily available; accessible to persons with disabilities; 
and recognized by health professionals and consumers alike. 
 
In order to achieve this vision, the Steering Committee believes that the following 
recommendations for statewide expansion of MOLST must be fulfilled: 
1. Statewide MOLST expansion should be strategic and occur over time to assure program 
integrity and promote appropriate use of MOLST. 
2. In keeping with the first recommendation, an organizational “MOLST home” and project 
coordinator should be designated with funding for three years to oversee MOLST 
expansion. 
3. Ongoing statewide access to MOLST and end-of-life care training should be available 
and promoted for health care professionals. 
4. An awareness campaign about end-of-life care in Massachusetts including MOLST 
should be conducted, as also recommended in the 2010 Report of the Massachusetts 
Expert Panel on End-of-Life Care. 
5. To assure continuous quality improvement and maintain program consistency and 
integrity, ongoing tracking and evaluation activities should be incorporated at the 
institutional level by all organizations implementing MOLST. 
In keeping with the spirit of collaboration, strategies for statewide implementation of MOLST 
should first include combining efforts with other initiatives with mutually enhancing aims, as 
well as beginning expansion with institutions that have shown interest in, and have capacity to, 
implement MOLST.  The MOLST Steering Committee looks forward to working with the 
Executive Office of Health and Human Services to further develop plans for MOLST expansion. 
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II. The Need for MOLST in Massachusetts  
Background 
As life expectancy has increased in the United States, many Americans experience chronic 
illness, disability, and periods of decline and frailty in the last years of life.  Ultimately, as the 
end of life approaches, seriously ill persons need to know that they will be cared for with 
compassion and dignity, according to their wishes.  Yet too often these wishes are unknown, 
unspoken or unavailable to health care providers at the time treatment decisions need to be 
made.  This can result in unmet needs, even discomfort for dying patients; disappointment and 
confusion for family members; and frustration and dissatisfaction for health care providers.   
For individuals with serious advancing illnesses who are not likely to recover, conversations 
about life-sustaining treatment preferences among the patient, the family and the clinician are 
of particular importance.  Such discussions are often difficult for everyone involved; however, 
they serve to help patients, their loved ones and health care providers better understand the 
patient’s medical condition, treatment options and goals of care. Without explicit 
understanding of patient preferences, health professionals may feel compelled to provide 
unwanted medical treatments to extend life, and these interventions can sometimes increase 
patient suffering and diminish quality of life at the end of life.1
Patient-centered care addresses and fulfills the needs, desires, and goals of care as expressed 
by the patient in the context of meaningful discussion with a health care provider and with 
family members.  In Massachusetts, however, even when patients with the gravest illness have 
had discussions with their clinicians and have made medical decisions related to life-sustaining 
treatments, there is no standardized way for them to express their preferences in such a way 
that they will be honored across the continuum of health care settings where end-of-life care is 
often provided (e.g. hospital, nursing home, outpatient, rehabilitation, etc.).  All Massachusetts 
adults can, and should be encouraged to, sign a health care proxy form to appoint a health care 
agent
  Conversely, health providers or 
family members may assume the patient wants comfort measures alone, resulting in less 
intensive medical interventions than the patient would otherwise have chosen. 
2 as a first step in the process of planning in advance for serious illness.  However, the 
process of appointing a health care agent through a health care proxy does not necessarily take 
into account specific medical conditions or decision points, and is often executed without input 
from a clinician.3
                                                          
1 Mack JW, Weeks JC, Wright AA, Block SD and Prigerson HG.  End-of-life discussions, goal attainment, and distress at the end of life: predictors 
and outcomes of receipt of care consistent with preferences. Journal of Clinical Oncology, 2010 Mar 1;28 (7):1203-8. 
   
2 The health care agent is the person authorized to make medical decisions on behalf of a patient who has lost capacity to make those decisions 
as determined and documented by the patient’s clinician. 
3 In 2005 a Massachusetts End of Life Commission (MEOLC)/AARP Massachusetts survey found that while 59% of respondents reported having 
signed a health care proxy form, only 17% had talked with their doctor about their end of life wishes. Dinger E.  Massachusetts AARP End of Life 
Survey  Washington DC,  2005) 
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To enable patients to communicate resuscitation preferences, the Comfort Care/Do Not 
Resuscitate (CC/DNR) Verification Protocol was established in Massachusetts in 1999.  The 
CC/DNR form gives emergency medical responders an actionable verification of existing DNR 
orders for persons in out-of-hospital settings.  However, this form is limited to EMT use in 
outpatient settings only, for resuscitation instructions only, and remains largely underutilized 
by many health professionals and patients to communicate patients’ preferences for 
resuscitation even in these limited circumstances. 
The absence of a standardized way to communicate patients’ life-sustaining treatment 
preferences across care settings is further complicated by a widespread lack of knowledge, 
comfort and skill for end-of-life medical decision-making in Massachusetts – among patients 
and health providers alike.  These manifest in the inconsistent use of end-of-life terms and 
mechanisms (e.g. proxy, agent, advance directive, living will4
However, despite these gaps and challenges, the Commonwealth has worked consistently over 
the past two decades to improve its end-of-life medical care.   With the passage of the Health 
Care Proxy Law in 1990 and the landmark Health Care Reform Act in 2006
); confusion about who can serve 
as an authorized medical decision-maker in various situations or settings; insufficient 
information about patient preferences; and many missed opportunities for important 
discussions between clinicians, patients, and patient representatives about the patient’s goals 
of care at the end of life.  
5, which included the 
creation of the Massachusetts Health Care Quality and Cost Council (“MHCQCC”), 
Massachusetts has shown a commitment to improving care for patients at the end of life.   
Based on the report of the MHCQCC End-of-Life and Chronic Care Committee in 2008, the 
Massachusetts legislature has called for several related initiatives6
• Creation of an expert panel on end-of-life care to recommend public policy and best 
practices for the delivery of such care to patients with serious chronic illness; 
:  
• Initiation of a public awareness campaign about the importance of end-of-life care 
planning; and 
• Establishment of a pilot program to implement and test a physician order for life-
sustaining treatment (POLST) paradigm program to assist individuals in communicating 
end-of-life care directives across care settings in at least one region of the Commonwealth. 
 
                                                          
4 Many patients, family members and health care agents don’t know that there is no legal statute in Massachusetts to authorize the content of 
living wills.  A comparison of end-of- life medical and legal instruments/terms is provided in Attachment G. 
5 Chapter 58 of the Acts of 2006, Massachusetts General Laws 
6 Chapter 305 of the Acts of 2008, Massachusetts General Laws 
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Massachusetts Medical Orders for Life-Sustaining Treatment:  MOLST 
 
The “Physician Order for Life-Sustaining Treatment (POLST) paradigm” was developed in 1991 in 
Oregon to address public concern that patients’ end-of-life medical treatment wishes were not 
known or were not being honored.  POLST programs feature “effective communication of patient 
wishes, documentation of medical orders on a brightly colored form and a promise by health 
professionals to honor these wishes.”7  Like some other states, in Massachusetts we call our 
program “MOLST” - with an “M” for “medical” orders.8
 
 
MOLST is a process and a standardized form used to translate life-
sustaining treatment preferences for patients across the life span 
into valid medical orders to be honored across all health care 
settings.  Based on the principle of patient self-determination and an 
individual’s right to accept or refuse medical care, MOLST is an 
appropriate way to meet the clinical standard of care for 
communicating and honoring patients’ life-sustaining treatment 
preferences across health care settings.9
 
   
MOLST is intended as a tool clinicians may use to document preferences about life-sustaining 
treatment after discussing with patients their medical condition, prognosis, the potential 
burdens and benefits of any recommended treatments, and the patient’s values and goals of 
care.  MOLST is intended for patients of any age who are nearing the end of life with a serious 
advancing medical condition, including (but not limited to) life-threatening disease or injury, 
chronic progressive disease and/or medical frailty.  MOLST use is voluntary and the MOLST 
form may indicate that the patient requests or 
 
refuses certain treatments.  MOLST reflects a 
patient’s current life-threatening medical condition and is not intended for routine use with 
patients who have early stage or stable medical conditions. 
The process begins with discussions about the goals of care between a clinician, patient and the 
patient’s loved ones and healthcare decision-maker(s).  These essential discussions to explore 
and clarify the patient’s condition, prognosis, and the benefits and burdens of treatment, as 
well as the values of the patient,  ensure that medical treatment decisions are clinically sound 
and based on the patient’s understanding and preferences.  Only then are treatment 
preferences documented as medical orders on the MOLST form.10
 
 
MOLST offers a significant new way for Massachusetts patients 
and families to make and express informed choices about life-
sustaining treatments.   Persons with serious advancing illness 
can now utilize MOLST with their clinicians to relay specific 
instructions about refusing or requesting a range of life-
sustaining treatments via medical orders to be honored by all 
                                                          
7 More POLST information may be found at www.polst.org. 
8 In Massachusetts and in other states, POLST/MOLST forms may be signed by physicians, nurse practitioners or physician assistants. 
9 Massachusetts Department of Public Health issued Circular Letter: DHCQ 10-02-529, endorsed by the Boards of Registration in Medicine, 
Nursing, and Physician Assistants and the Office of Emergency Medical Services  
10 The Massachusetts MOLST form is provided in Attachment A. 
“Sometimes we view these things 
with skepticism …aggressive 
treatment versus DNR…Who decides 
what gets offered to us?…For me, 
the MOLST form can indicate what 
we  want…they can’t assume that 
they would want the same things.” 
-  African American focus group 
participant 
“To me, in this form here, 
you are empowering 
patients with these words.  I 
think that this is great and I 
want it for me.” 
-  General community focus 
group participant 
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health professionals in any care setting, including at home.  The potential of MOLST in 
Massachusetts includes:  increased shared end-of-life medical decision-making; increased 
adherence to patients’ life-sustaining treatment preferences; and decreased provision of 
burdensome medical tests and treatments to patients who do not want them.  
 
III. The MOLST Demonstration Experience  
Charge and Leadership 
In response to the Massachusetts legislation mandating the establishment of a pilot program to 
implement and test a POLST paradigm program… in at least one region of the Commonwealth11
 
, 
a state-level, multi-sector Steering Committee was convened in 2008.  With oversight from the 
Massachusetts Executive Office of Health and Human Services Department of Public Health and 
the Executive Office of Elder Affairs, program management was provided by the Center for 
Health Policy and Research at Commonwealth Medicine, a division of University of 
Massachusetts Medical School.  The Steering Committee’s task was to plan, design and 
demonstrate how Medical Orders for Life-Sustaining Treatment could be implemented in 
Massachusetts, including education for health professionals; outreach to patients and 
caregivers; the development of measures to test the success of the program; and the 
development of recommendations for the establishment of a statewide program.   
Selecting the Demonstration Locale  
The Steering Committee selected the Greater Worcester area for the demonstration based on a 
number of factors including: size of the geographic area12; access to health care institutions 
with established referral patterns and shared patient flow; clinical leadership from University of 
Massachusetts Memorial Health Care; and prior experience with successful community 
collaboration to improve end-of-life patient care through the Better Ending Partnership, a 
Worcester-based end-of-life coalition which promoted advance care planning and the use of 
health care proxies in central Massachusetts during the previous decade .13  Nine organizations 
representing a variety of health care settings were then recruited as implementation sites: two 
acute care hospitals14
 
, three nursing homes, two hospices, one managed care practice and local 
emergency medical services. 
 
                                                          
11 Chapter 305 of the Acts of 2008, Section 43, Massachusetts General Laws 
12 With an estimated population of 182,882 (2009), Worcester is the third largest city in New England.  Source:  census.gov. 
13 Better Ending Partnership was a community coalition of professional, civic, business, and religious leaders committed to improving end-of-life 
care in the central Massachusetts region from 2002 to 2009.  A major initiative of the Partnership was the production and dissemination of the 
Guide for a Better Ending, a consumer educational brochure about advance care planning.  See www.betterending.org. 
14 One of the acute care hospitals joined the demonstration at a later date than the other sites and soon lost the primary site-level “MOLST 
champion” to a different health care institution.  As a result, the hospital did not begin utilizing MOLST with patients during the demonstration 
period. 
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Community Engagement 
Throughout all phases of the MOLST demonstration program, 
input from both the lay community and the health care 
community was encouraged, solicited and incorporated.   
 
To gain perspectives on MOLST from the diverse consumer base in 
Worcester, 59 participants were recruited for five focus groups 
facilitated by the Central Massachusetts Area Health Education 
Center, Inc., a partner in previous Worcester-based Better Ending 
Partnership initiatives.   The groups were comprised of English-
speaking Caucasians, Spanish-speaking Latinos, English-speaking African-Americans, 
Vietnamese speakers, and individuals with various types of physical and mental disabilities 
residing in the Worcester area.  Ten key stakeholder interviews were also conducted with select 
local community leaders and informants.  Consumer perspectives were considered in 
developing the MOLST process, form and materials, in order to be as patient-centered as 
possible and to be responsive to the wide array of cultural perspectives about end-of-life and 
health care that were shared.  Key consumer input included concern about the manner in which 
MOLST would be presented and the support that would be offered to patients; the need for 
(and doubt of receiving) ample clinician time to explain all aspects of MOLST; themes of 
mistrust and past difficult experiences with health care providers; the integral role of the family 
in MOLST discussions and decision-making; the importance of attending to relevant cultural and 
linguistic dynamics and needs during the patient-provider encounter (including interpretation 
and translation); the need for more explanation about end-of-life decision-making and tools 
(especially how MOLST differs from the health care proxy, DNR orders and living wills); and a 
general and unanimous dislike of the term “MOLST.”  Significantly, the participants 
recommended that the content of the MOLST form, along with descriptions of the potential 
treatments, be translated into Spanish and Vietnamese to assist speakers of those languages to 
better comprehend the nature of the medical interventions.   Participants also made 
recommendations regarding how to make information accessible to persons with disabilities, 
particularly those with visual and auditory disabilities.  All of the groups and interviewees 
repeatedly expressed recognition of the value and utility of MOLST.   
 
Health professionals were also engaged from diverse health care settings and communities via 
presentations at multiple health care and professional organization 
settings and through face-to-face key stakeholder interviews.  
Perspectives from potential clinician signers of the MOLST form as 
well as from nurses, social workers, clergy, emergency responders, 
medical interpreters, and other health professionals who could 
potentially engage with patients and families in the MOLST process 
were intentionally garnered to assure medical integrity and clinical 
relevancy.  Key feedback included support for the intent and 
 “We would have been afraid to 
talk about this before…but 
because of the education we 
have gotten in the past few 
years about the health care 
proxy, here at the senior center, 
we are ready now to talk about 
this…this very helpful.”  
– Vietnamese focus group 
participant 
“Please…make sure you 
involve the family!!  If the 
doctor knows that they are 
going to talk about this, 
have the person bring a 
family member!”  
– Latino focus group 
participant 
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potential of the MOLST program; the need for engaging in more of these important 
conversations with patients and their families; lack of clarity about the terms used and available 
resources for end-of-life care planning; and the desire for more related information and 
training.    
 
Massachusetts MOLST Form 
The creation of the initial demonstration MOLST form tailored for use in Massachusetts was an 
iterative process involving substantial and frequent modifications to the wording, concepts and 
format based on input from scores of health care professionals (including physicians, nurses, 
nurse practitioners, social workers and emergency medical personnel) as well as diverse 
consumer groups. Time was spent reviewing other states’ POLST forms and then adapting them 
to reflect the social, medical, and legal environment in Massachusetts as well as the lessons 
learned when the Massachusetts Comfort Care/Do Not Resuscitate Verification Protocol 
(CC/DNR) form was introduced. The resulting MOLST form differs from other states’ POLST 
forms in several respects, with medical orders for use in emergent situations on the first page 
and a series of patient preferences about other possible life-sustaining treatments on the 
second page. The form allows the patient and clinician to indicate that a particular issue was 
not discussed or that no decision was reached. The intent is to create a document that 
facilitates succinct communication of accurate information reflecting individualized treatment 
preferences across settings of care.   Final changes were made based on feedback received 
during the demonstration program and, as finally proposed, the Massachusetts MOLST form 
meets with widespread approval from demonstration site participants and other health care 
professionals and consumers.   
 
Demonstration Site Preparation  
Between January and December of 2010, each demonstration site provided one or more key 
personnel to champion and coordinate site-level MOLST implementation. These individuals 
engaged in the substantial tasks of preparing institutional policies, protocols and infrastructure; 
identifying training strategies for staff and venues; creating tools and methods for tracking 
MOLST activity; and overall oversight and troubleshooting during MOLST implementation.  
These “champions” also engaged with one another across demonstration sites via regular 
meetings and consultations with clinical liaisons from the MOLST planning team, to discuss 
experiences, issues, successes and challenges arising during  MOLST implementation at their 
respective sites.  In February 2010, a MOLST launch event was held in Worcester with 
approximately 150 attendees from all sectors of the health care system as well as community 
participants.  At the same time, the Massachusetts Department of Public Health issued Circular 
Letter: DHCQ 10-02-529, endorsed by the Boards of Registration in Medicine, Nursing, and 
Physician Assistants and the Office of Emergency Medical Services, to inform and prepare its 
regulated entities about the MOLST demonstration program.  
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Training and Outreach  
Ensuring that health care professionals understand the purpose 
and the use of MOLST is essential to its implementation.  
Numerous questions arose in the course of MOLST training, not 
only about the use of the form but also about medical decision-
making and communicating with patients about end-of-life 
issues.  Successful implementation therefore requires not only 
disseminating information but also providing opportunities for 
trainees to ask question as well as a chance to participate in 
dialogue about their concerns.  Accordingly, more than 1200 
administrators, clinicians, and other health and social service 
professionals from the MOLST demonstration sites and 
approximately 700 emergency medical technicians15 participated in face-to-face MOLST 
training, orientation or presentations.  Outside of the demonstration sites, another 700 
clinicians, health and social service professionals, first responders, policymakers, consumers, 
patient advocates and stakeholders also received face-to-face MOLST informational sessions.  
In addition, thousands of consumers, health professionals and other stakeholders received 
information about MOLST via print materials, video and/or the MOLST website at www.molst-
ma.org.  
 
MOLST Utilization with Patients 
Clinicians began using the MOLST form with patients on April 1, 2010 at eight Greater 
Worcester area demonstration sites: three nursing homes, two hospices programs, one acute 
care hospital, one geriatric home-based physician program, and Region 2 emergency medical 
services.   
 
After institutional MOLST policy and procedure development, the nursing homes introduced 
MOLST first to their nursing home patients who had already chosen to limit treatment (through 
DNR orders, for example) 16
 
 or who were being transferred to hospitals or other care settings. 
Later MOLST was introduced to nursing home patients and their families during periodic care 
review meetings and to new admissions to the facility.    
The acute care hospital, the largest and most complex of the demonstration sites, implemented 
MOLST slowly but steadily.  After developing and approving an institutional policy and 
procedures to incorporate MOLST into current practices, use of the MOLST form advanced 
                                                          
15 Data provided by OEMS capture only EMTs who applied for OEMS MOLST training credits; the actual number trained (including local 
fire/police first responders) is higher.  OEMS data were not tracked by region, though it is known that EMTs from most if not all regions of 
Massachusetts participated in MOLST training. In November 2010 there were approximately 24,000 EMTs in the Commonwealth, including 
basic, intermediate and paramedic levels.  Therefore, a very large number of EMTs will still require MOLST training.  
16 One nursing home administrator reported that 95% of their long term care patients already had DNR orders and so clinicians saw no urgency 
in also offering MOLST forms. 
 “It is very, very important for the 
doctor to be sensitive….ask the 
patient first if they are 
comfortable talking about 
this…respect their religious 
beliefs and their language…make 
sure they understand what you 
are saying…if they don’t, use an 
interpreter.  If they (patients) are 
not comfortable, maybe they will 
let you talk with their 
family…that can be their 
emotional support.”  
– Vietnamese focus group 
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primarily in relation to the degree of awareness, interest and leadership of clinicians in various 
departments or inpatient floors, the strongest of which was in the hospital medicine service.  
Although it was not feasible for the hospital to track the number of MOLST discussions or forms 
signed throughout the demonstration program, a chart review of patients discharged from the 
hospital medicine service on three different days during the demonstration program showed an 
average of 20% of patients with inpatient limitation of treatment (LOT) orders had a signed 
MOLST form at discharge.  Also noted during the demonstration time frame was an increase in 
the overall numbers of patients with LOT orders while hospitalized.17
 
  By the end of the 
demonstration period, the hospital had plans for embedding MOLST into its quality 
improvement initiatives with the intention of continuing to offer to patients with serious 
advancing illness the opportunity to discuss life-sustaining treatments and documenting their 
preferences on a MOLST form.      
The emergency department (ED), typically located within a hospital facility, is considered an 
outpatient clinical setting by regulation.   Therefore, a separate policy and procedures were 
required to address the particular needs of that setting of care.   The consensus among ED 
personnel was that the bedside nurse was the most likely person to take responsibility for the 
MOLST form, by entering that information into a medical record (whether paper or electronic), 
and by communicating to the rest of the clinical team the presence of a MOLST form.    
 
MOLST implementation in the geriatric managed care home visiting 
program proved to be a “good fit” for several clear reasons:  patients 
were enrolled because of specific medical conditions that also made 
them suitable for MOLST; nearly all of the patients had capacity to 
engage in goals of care discussions and were able to sign the MOLST 
forms themselves; and monthly home visits conducted by nurse 
practitioners allowed for discussions to occur over time with clinicians who had authority to 
sign MOLST forms with patients.  Between April and November, 44% of enrolled patients were 
offered MOLST as an option, and half of them elected to sign MOLST forms. 
 
Reports of emergency medical technician (EMT) encounters with patients who had signed 
MOLST forms in the field were relatively few due to the limited scope and time frame of the 
demonstration program.  However, in the situations when MOLST forms were encountered, 
EMTs reported that the MOLST provided instructions that were helpful and were honored as 
appropriate.   The Emergency Medical Control physicians, who are in radio contact with EMTs, 
reported that the usual procedure in their experience for honoring a CC/DNR form “in the field” 
is to communicate with Medical Control to get “permission” to honor the DNR order.  The 
expectation from the Medical Control physicians was that the EMT would do the same when 
                                                          
17 This was probably due to a combination of improvements made in the hospital’s electronic documentation tool for limitations of treatment 
(LOTs) and/or increased conversations about end-of-life care. 
“They should be offered 
support at the same time 
they are given this 
information.” 
- General community focus 
group participant 
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they encounter a MOLST “in the field.”  While this was not part of the official policy and 
procedure outlined, it seems to be the general practice within the region of the demonstration.   
 
Hospice programs utilized the MOLST form less.  Because most patients enrolled in hospice 
have already engaged in extensive discussions about goals of care and have already established 
life-sustaining treatment preferences, hospice personnel suggested that waiting to complete 
the MOLST form at this late stage was less likely to benefit most hospice patients.18
  
  Still, 
hospice personnel indicated that MOLST could potentially help patients and their families 
engage in these important discussions and begin the decision-making process if it were 
introduced at earlier stages in their disease.   
MOLST utilization in 
select demonstration 
sites 
Number 
of 
patients 
Number of patients 
offered MOLST  
(% of all patients) 
Number of MOLST 
signed  
(% of all patients) 
Patients offered 
MOLST who signed 
MOLST form (%) 
Nursing Homes (n = 3) 351 65 (19%) 45 (13%) April – August 69% 
Geriatric Home Visiting 
program 
260 115 (44%) 58 (22%) April – 
November 
50% 
 
It is important to recognize that because use of the MOLST form is voluntary, the measure of 
implementation success is not the quantity of signed MOLST forms, but the number of suitable 
patients who were offered the opportunity to utilize MOLST to reflect the discussions that took 
place prior to signing MOLST forms.  At the same time, it is very difficult to determine the 
“denominator” – that is, the total number of patients who are suitable for MOLST.   This 
denominator is not easily determined by a patient’s age or diagnosis because every individual 
and situation is different.  In fact, determining which patients may be suitable for or benefit 
from utilizing MOLST can be more of an art than a science.   
 
It is also important to note that well over half of the patients who signed MOLST forms had DNR 
orders already, yet elected to sign a MOLST form, indicating a desire to express preferences 
about a wider range of life-sustaining treatments than previous documentation tools allowed.   
 
The MOLST demonstration program was neither designed nor expected to evaluate patient 
outcomes, or the degree of adherence to patients’ preferences.  However, the question of 
whether patients with MOLST forms were more likely to have their life-sustaining treatment 
preferences known and honored at the end of life than patients without MOLST forms is one 
that should be explored.  This type of evaluation will become possible as individual institutions 
begin to implement, embed and measure MOLST patient outcomes as part of their ongoing 
quality improvement initiatives. 
 
                                                          
18 Like the nursing homes, the hospice programs did offer and sign MOLST forms with a few patients who were transferred to hospitals or other 
settings. 
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Lessons Learned19
The MOLST demonstration provided the opportunity to: observe and test the process of MOLST 
implementation in various types of health care settings; track elements that inhibited or 
enhanced utilization; and note intervening or emerging issues.  Some of the key findings in 
these areas were: 
 
• MOLST can be implemented effectively in most institutions in a relatively short period of 
time with the appropriate commitment of time and other resources;  
• Adequate time must be invested in the preparatory work of developing MOLST policies 
and procedures, and approval processes; 
• Institutions need an on-site “MOLST champion” to succeed with MOLST 
implementation;  
• Health professionals need training and access to ongoing coaching, support, and 
troubleshooting during MOLST implementation; 
• Health professionals need training about how to discuss patient-centered medical 
decision-making, end-of-life care and goals of care with patients and their families; 
• Patients, families and health professionals all need more education about end-of-life 
care terminology, related Massachusetts laws and medical decision-making processes;  
• Limited clinician time for discussions with patients and families is a barrier in every
setting; 
 
• Patients want to use MOLST not only to document their 
preferences to limit life-sustaining medical treatment, 
but also to affirm their wish to accept life-sustaining 
treatment;   
• Engagement and collaboration with individuals in the 
community is important because MOLST implementation 
must be individualized for every site and setting; 
• Limited access to health care agents (for signatures) slows 
the process in nursing homes and at the time of 
discharge from acute care hospitals; 
• EMTs who received MOLST training found the transition to MOLST from the CC/DNR 
form easy and considered MOLST to be a better form;  
• The emergency room is a challenging place to implement MOLST in the hospital because 
of competing demands for clinician attention, variable patient populations, and the 
intense, busy setting; 
• Health professionals in all the demonstration site settings considered MOLST an 
improvement over existing documentation tools/systems; 
                                                          
19 More detailed lessons learned in the demonstration sites are provided in Attachment B. 
 “We are not heard, we are not 
listened to…it’s like we don’t 
have the capacity to make our 
own decisions…MOLST could help 
us make our choices known and 
adhered to…that’s why it’s 
important to state that the 
MOLST will be honored, not may 
be honored.”  
– Persons living with disabilities 
focus group participant 
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• All the demonstration sites plan to continue using MOLST beyond the demonstration 
period. 
 
 
 
 
 
 
 
 
 
 
 
IV. Recommendations for MOLST Expansion 
Although the MOLST Demonstration Program was complex and challenging on many fronts, the 
experience elicited overwhelming interest in and support for the MOLST process and form.  
Strong interest emerged not only from the demonstration sites, but also from numerous other 
public and private health care institutions, from professionals and consumers alike – all of this 
during a time of public conflict about end-of-life medical care related to national health care 
reform. The Steering Committee continues to field increasing requests for information and 
assistance from health care organizations throughout the Commonwealth that are eager to 
begin implementing MOLST with their patients. 20
 
  It is clear that MOLST addresses an 
important unmet need in Massachusetts by providing a standardized process and tool for 
clinicians, patients and their families to discuss, understand, and arrive at challenging health 
care decisions and to communicate those decisions across health care settings.  
Moreover, the demonstration experience suggests that MOLST fits well into Massachusetts’ 
existing health care system reform goals.  For example, there appears to be significant potential 
for MOLST to positively impact quality of care and to promote principles of patient-centered 
care.   Based on findings from other POLST paradigm states and end-of-life care research, 
MOLST will likely promote patient choice and improve the quality of shared medical decision-
making and thus provide for more patient-centered use of health care resources.  In some cases 
this could help to ease transitions of care between institutions and reduce avoidable hospital 
re-admissions as well as avoid extended end-of-life hospital stays for patients who have 
expressly stated that they do not want them.  Therefore, 
                                                          
20 MOLST planning has begun at Harvard Vanguard, Partners HealthCare System and Children’s Hospital of Boston, for example.  
“This is a beautiful way to be able to take care of your loved ones’ last moments. I am at peace with my Mother’s 
death…we were there with her the whole time…I feel pride that, as a family, we could take care of her every 
need…she had dignity and respect and comfort as she moved on to her next life.” 
– Latino focus group participant 
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The MOLST Steering Committee recommends expanding MOLST 
implementation beyond the demonstration area beginning in 2011, with the 
ultimate goal of full statewide MOLST implementation by January 201421
 
, in 
keeping with the following vision and specific recommendations: 
 
VISION 
In Massachusetts, 
 
 Every suitable patient will be offered the opportunity to utilize a MOLST form in concert with 
that patient’s clinician to communicate life-sustaining treatment preferences across health 
care settings;  
 Every EMT will receive MOLST training and be authorized to honor valid MOLST forms;  
 Every major hospital system and health care plan will implement policies and procedures to 
facilitate the appropriate utilization of MOLST by clinicians and patients;  
 Every clinician will seek to improve communications skills with patients nearing the end of 
life; have access to MOLST education; and be encouraged by professional organizations and 
regulatory bodies (e.g. Boards of Registration, Massachusetts Medical Society) to utilize 
MOLST correctly;  
 MOLST forms as well as education and outreach materials will be uniform; linguistically 
appropriate; culturally relevant; easily available; accessible to persons with disabilities; and 
recognized by health professionals and consumers alike. 
 
 
Recommendations 
1) Statewide MOLST expansion should be strategic and occur over time to assure program 
integrity and promote the appropriate use of MOLST. 
The use of MOLST as a tool to document decisions about life-sustaining medical treatments will 
provide the greatest benefit to patients, providers, and health care institutions when all have 
been properly trained and informed.  To achieve the anticipated benefits of the program, a 
facilitated, step-wise rollout of the program is recommended.  Full statewide implementation of 
MOLST in Massachusetts will require: 
 
• Cultural change as health professionals and patients learn about and understand the 
intent and use of MOLST; 
                                                          
21 The recommendation to expand MOLST is supported by the Massachusetts Expert Panel on End-of-Life Care; the Massachusetts Health Care 
Quality and Cost Council; the Massachusetts Board of Registration in Medicine; the Massachusetts Care Transitions Forum; Greater Boston 
Legal Services; and Health Care for All.  Did I hear Martina say there is a new name for the Expert Panel?  
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• Community change as communities plan MOLST implementation strategies with the 
best chance for success; 
• Organizational change as hospitals, nursing homes, hospices, home health agencies, 
multi-specialty provider groups, insurers, physician practices and emergency responders 
expand their policies and procedures to utilize MOLST;  
• Individual change as clinicians and patients learn about and adopt the MOLST process 
and form correctly as an appropriate way to meet the clinical standard of care for 
communicating patient preferences about end-of-life medical treatment across health 
care settings.   
 
2) In keeping with the first recommendation above, an organizational “MOLST home” and 
project coordinator should be designated with funding for three years to oversee MOLST 
expansion.  
The demonstration experience and continuing requests from health care organizations and 
individuals needing assistance with MOLST planning and use strongly support the need for a 
MOLST institutional home and dedicated staff.  Full statewide expansion will require expertise 
to:  
 
• Identify, coach and support institutional MOLST champions and teams;  
• Coordinate expansion efforts between institutions, payers, patient groups, and 
providers;  
• Assure a mechanism for reaching final decisions about changes to, and maintaining 
standardization of, the MOLST process and form;  
• Track MOLST implementation progress; maintain and assure the relevancy and quality 
improvement of the MOLST website, training modules and educational outreach 
materials;  
• Provide and facilitate technical assistance for communities and providers implementing 
MOLST; 
• Engage individuals and organizations in communities in order to adapt implementation 
strategies to community needs;  
• Communicate about MOLST with state government, health care systems and the public.  
 
3) Ongoing statewide access to MOLST and patient-centered end-of-life care training should 
be available and promoted for health professionals. 22
Training of health professionals throughout the workforce is needed to maintain the patient-
centeredness of the project and the appropriate emphasis on the MOLST communication 
process – especially the importance of goals of care discussions prior to completing MOLST 
forms and increased capacity of clinicians to engage in such conversations.  The demonstration 
training materials and MOLST website, with additional adaptations, provide a solid foundation 
 
                                                          
22 A plan for statewide training is required for endorsement of statewide programs by the National POLST Paradigm Task Force. 
19 
and platform for training.   Specific recommendations related to training health professionals 
include to: 
• Establish webinars and/or statewide conference calls for MOLST training, 
troubleshooting and coaching; 
• Create online training modules for professionals and track participants; 
• Develop multimedia and video training about patient-centered end-of-life care 
conversations; 
• Provide CMEs, CEUs, risk management credits, etc. for completion of MOLST training; 
• Require MOLST training for Emergency Medical Technicians (EMTs);   
• Collaborate with the Massachusetts Medical Society (MMS) for continued support of 
physician training for end-of-life care;  
• Train a core of authorized MOLST training consultants, i.e. train-the-trainer sessions for 
EMS Regions I-V; 
• Develop training for supporting professionals, such as medical interpreters, patient 
navigators, and geriatric care managers to assist patients and families in understanding 
MOLST. 
 
4) An awareness campaign about end-of-life care in Massachusetts including MOLST should 
be conducted, as recommended in the 2010 Report of the Massachusetts Expert Panel on 
End of Life Care.   
Such a campaign is vital to:  
• Enhance  public understanding and build a common 
vocabulary for these important end-of-life care 
conversations; 
• Educate the public about information and resources related to end-of-life care in 
Massachusetts;  
• Inform patients and families about medical decision-making in Massachusetts – 
especially about the vital role of the health care proxy and the MOLST process and form;  
• Inform physician offices and groups about the MOLST process and form;  
• Build a common understanding and trust between health professionals and the public 
about the intent and potential of MOLST to increase adherence to patients’ end-of-life 
care treatment preferences.  
 “This MOLST…maybe this can 
help us be heard.” 
– Persons living with disabilities 
focus group participant 
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5) To assure continuous quality improvement and maintain program consistency and 
integrity, ongoing tracking and evaluation activities should be incorporated at the 
institutional level by all organizations implementing MOLST. 
Tracking and evaluation will be essential for determining the extent to which MOLST is being 
adopted and implemented in different parts of the Commonwealth to achieve full statewide 
expansion.  These activities will: 
 
• Promote the sharing of lessons learned from MOLST implementation in new 
communities;  
• Provide important information about MOLST utilization, applicability and barriers for a 
diverse range of cultural, linguistic, and underserved populations in new communities;  
• Assure appropriate use of the MOLST process and form.  
 
V. Strategies for MOLST Expansion  
Statewide implementation of MOLST should be accomplished by bringing a variety of key public 
and private agencies, organizations and institutions together to leverage the work already 
underway to improve the quality of medical care for patients in Massachusetts.  Accordingly, 
we propose the following two phases and a suggested cast of “key players” for expanding 
MOLST statewide.   
 
Phase One – Expansion through Strategic Collaboration and/or Capacity 
 
Improving clinician, patient, and family communication in 
order to improve patient-centered care near the end of life, 
especially through goals of care discussions and shared 
medical decision-making, is a major aim of MOLST.   Other 
important goals of MOLST are to increase documentation 
about patient preferences and to improve communication 
among providers and between institutions during transitions of care, which can improve the 
quality of end-of-life care.  There is great potential to achieve these goals through synergy with 
an impressive number of high-level, cross-continuum initiatives currently underway in 
Massachusetts.  MOLST “champions” may be readily identified among participants of the 
initiatives listed in the table below.  For example, the State Action on Avoidable Hospital 
Readmissions (STAAR) initiative aims to reduce all-cause 30-day re-hospitalizations and to 
increase patient and family satisfaction with transitions and coordination of care.  Hospitals 
involved in the STAAR initiative will likely be eager to implement MOLST since it has the 
potential to reduce the occurrence of re-hospitalization for patients who prefer to remain in 
the home or a home-like setting at the end of life.   
Strategic Collaboration 
“Listen to what we want…be sensitive 
and patient…explain every detail…and 
provide support…don’t just give us a 
pamphlet and send us home.”   
-  General community focus group 
participant 
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As aptly stated by one member of the Massachusetts Health Care Quality and Cost Council and 
the MOLST Steering committee:  “None of these initiatives can go out in its own silo; MOLST is 
mutually beneficial and co-dependent on all these other things.” 
 
CURRENT INITIATIVES MUTUAL AIMS  
Medical Orders for Life-
Sustaining Treatment (MOLST) 
Improving clinician, patient, and family communication about end-of-life 
medical care in order to improve patient-centered care 
 
Increasing documentation and communication of patient preferences across 
the care continuum, resulting in improved care transitions; fewer avoidable 
hospital readmissions; and more meaningful use of resources 
 
Increasing education and awareness about medical decision-making and end-
of-life care issues and resources among health professionals and consumers, 
including disseminating best practices and lessons learned 
 
Engaging community members, health professionals, policy makers and other 
stakeholders in improving the quality of end-of-life care 
Massachusetts Expert Panel on 
End-of-Life Care 
State Action on Avoidable 
Hospital Readmissions (STAAR) 
initiative 
Massachusetts Care Transition 
Strategic Plan  
INTERACT II (in 100 nursing 
facilities) 
Common Framework for 
Personal and Public 
Engagement in Health Care 
Massachusetts hospital quality 
improvement initiatives 
 
“Capacity” refers to promoting MOLST expansion first in organizations or institutions that have 
demonstrated both interest in MOLST and also the capacity to implement MOLST effectively.  
This would also include expanding MOLST implementation to other health care organizations 
and institutions in the Worcester area.  Beyond the Worcester area, several health care 
institutions with significant capacity to implement and expand MOLST within their various 
systems have already approached the Steering Committee with requests to begin MOLST 
implementation.   
Capacity 
  
Phase Two – Expansion by Geographic Region 
Once Phase One is well underway and MOLST has been rolled out in organizations with capacity 
through strategic collaboration, it will be possible to assess the extent to which MOLST has 
extended to other geographic areas in Massachusetts.   If MOLST is not already being 
championed and implemented in most regions of the Commonwealth (e.g. North Shore/Salem, 
South Shore, Metro-West, Cape Cod, Boston, Western Massachusetts, Springfield), then it will 
be advisable to identify and support individuals and/or organizations who can champion, 
develop and implement MOLST in every region.   
 
Key Players 
The successful expansion of MOLST would benefit from the support and involvement of several 
public and private state-level entities with regulatory, sub-regulatory, membership, collegial 
and/or other relationships with the Massachusetts health care community.  Although others 
are sure to emerge, key players (and their possible involvement) may minimally include: 
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ORGANIZATION SUGGESTED ROLE 
Massachusetts Department of Public 
Health (DPH) 
Continue supporting MOLST as an appropriate way to meet the clinical 
standard of care for communicating patients’ life-sustaining treatment 
preferences across care settings 
Release a circular bulletin in 2011 to licensed hospitals, long term care 
facilities, licensed ambulance services, and EMTs validating the 
utilization and honoring of MOLST 
Require MOLST training for EMTs 
Plan and facilitate a timeline and strategy to eventually phase out the 
CC/DNR verification protocol form as MOLST becomes the 
communication tool/document of choice 
Massachusetts Executive Office of 
Elder Affairs (EOEA) 
Provide training on end-of-life issues, including MOLST, for 
Massachusetts Family Caregiver Support Program specialists, home care 
program providers, Information and Referral staff, and Aging and 
Disability Resource Consortia (ADRC) member agency staff  
DPH/EOEA Collaboration Facilitate communication among key state agencies to determine 
initiatives related to family caregiver support and end-of-life discussions  
Identify ways to increase support for family caregivers caring for loved 
ones at home 
Continue to provide leadership throughout the expansion period of 
MOLST 
Promote consumer and provider education about MOLST via Aging 
Services Access Points (ASAPs), Senior Centers/Councils on Aging, 
primary care clinicians, community health centers, and other community 
health programs 
Massachusetts Boards of Registration 
in Medicine, Nursing, and Physician 
Assistants 
Continue supporting MOLST as an appropriate way to meet the clinical 
standard of care for communicating patients’ life-sustaining treatment 
preferences across care settings 
Massachusetts Hospital Association 
 
Provide Massachusetts hospital leadership with information about the 
intent and purpose of MOLST for patients 
Massachusetts Medical Society; 
Massachusetts Nurses Association; 
Association of Physician Assistants 
Communicate about and promote the use of MOLST with Massachusetts 
clinicians 
Continue to support end-of-life care professional education that 
incorporates CMEs, CEUs, risk management credits, etc. 
Massachusetts Health Data Consortium Communicate MOLST progress and issues to the Care Transitions Forum 
members 
Help organize public events similar to the MOLST launch event  in 
February 2010  
Include MOLST in other Massachusetts health policy discussions 
concerning issues such as payment reform, quality improvement, 
patient-centered medical homes, health information 
technology/exchange, and accountable care 
Massachusetts Home Care Alliance; 
Mass Aging; League of Community 
Health Centers; Massachusetts Senior 
Care Association; Hospice and Palliative 
Care Federation of Massachusetts 
Promote dissemination of MOLST training resources  and information to 
health professionals and consumers 
Help build a common language and understanding about end-of-life care 
terms, issues and resources in Massachusetts  
Massachusetts Association of Health 
Plans 
Support the use of MOLST by including end-of-life care measures and 
documentation of MOLST conversations with appropriate patients as 
quality indicators 
Promote payment mechanisms for the time clinicians spend on MOLST 
conversations  
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Finally, full statewide expansion of MOLST should include a concerted effort to engage the 
support of key consumer groups and community organizations, such as Health Care for All, 
Partnership for Healthcare Excellence and Area Health Education Centers, as well as faith-based 
and fraternal organizations.  These organizations can be encouraged to endorse MOLST as a 
way to improve the quality of care at the end of life and to promote awareness of MOLST and 
its potential among their members and constituents.  
 
Conclusion 
The Medical Orders for Life-Sustaining Treatment Demonstration Project has shown that 
MOLST is needed and desired in the Commonwealth by health care professionals and 
consumers alike.    Full statewide MOLST implementation will require strategic oversight, 
financial resources, technical assistance and coaching from dedicated MOLST staff, as well as 
ample planning, championship and monitoring within institutions.  Despite these challenges, we 
believe that the potential of MOLST is significant and inspiring.  Statewide implementation of 
MOLST will improve quality of life for patients nearing the end of life and will advance the 
capacity of institutions in the Commonwealth to achieve health care reform, enable more 
patient-centered care, enhance quality of care, and use system resources more efficiently.  The 
MOLST Steering Committee looks forward to working with the Executive Office of Health and 
Human Services to establish an ongoing “home” for the MOLST project and to further develop 
these plans and strategies for the full statewide expansion of MOLST. 
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Attachment A 
 
MA MOLST Form 
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Attachment B 
Key Findings from MOLST Demonstration Site Implementation 
 
Nursing Home (NH), Home Health and Hospice Sites 
Notre Dame Long Term Care Center (121 beds) 
Jewish Health Care (141 beds) 
Shrewsbury Nursing and Rehabilitation Center (103 beds) 
UMass Memorial Home Care and Hospice (home-based – no beds) 
VNA Care Hospice (primary demonstration role was collaboration with Fallon Clinic) 
 
Notes:  20 total nursing homes in Worcester, 3 in the MOLST demonstration; beds in demonstration = 
365 (15% of Worcester nursing home beds); 8 hospice programs in Worcester, 2 in demonstration 
 
Key Findings: 
• All the sites introduced MOLST starting with the “highest risk patients” and patients going out and 
returning from hospitals, then with patients during admission and at annual case reviews. 
• Not many MOLST forms were signed with patients who already had CC/DNR form – mostly for lack 
of clinician time (since orders were already in place) especially for the patients at “home” in the NH 
(i.e. not planning to return to their private homes or elsewhere). 
• Both page one and page two of the MOLST form quickly became regarded as “official.”  Though page 
two did not get utilized as much as page one, it was probably mostly because of clinician’s lack of 
time. 
• Clinical staff perceived that MOLST “has more power” than the CC/DNR because it is an actual 
medical order. 
• Policies stated that the MOLST form should be honored if a patient with a MOLST had a crisis before 
the clinician had a chance to “translate” the MOLST into NH orders. 
• Clinical staff who had experience with the CC/DNR form were quick to understand the concept and 
utility of MOLST. 
•  A “majority” of patients in the NHs lacked capacity; therefore, the health care agent was usually the 
decision maker. 
• A barrier for all NHs was delays in getting health care agent signatures.  
• Getting patients’ MOLST forms back from hospitals and other settings was also problematic in some 
cases. 
• In the NHs nearly every patient given the option of using MOLST accepted.  “By this time, at this 
stage the patients and their families are ready for it.” 
• The MOLST educational materials were thought to be very helpful.  It will be important to have print 
materials continue to be available because many NH don’t have internet access or resources to 
download info from website. 
• Staff development coordinators, medical directors and directors of nursing in NHs should be the 
primary staff to receive MOLST information and outreach. 
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• Suggested minimal contents of NH tool kit: Sample MOLST policy for long term care centers; MOLST 
video; PowerPoint staff training module; MOLST coordinator to call when they have questions. 
• Suggested minimal training elements for NH staff: “This is the MOLST form; this is what and who 
MOLST is for; this is how to do it; and to better explain the relationship between the front and the 
back of the form.” 
 
Acute Care Hospital Site23
UMass Memorial Health Care (Hahnemann, Memorial and University Campuses) 
 
Notes:   781 beds; 1200+ active medical staff (www.umassmemorial.org) 
 
“Snapshot” - MOLST utilization on three days in Hospital Medicine Service, Memorial Campus – UMass 
Memorial Medical Center: 
 
2010 April June August** November** 
Total patients on Hospital Medicine service 45 42 45 54 
Total with limitation of treatment (LOT) while inpatient 5 (11%) 3 (7%) 9 (20%) 10 (19%) 
Total with MOLST at discharge 1 (20%) 0 (0%) 3 (33%) 3 (30%) 
Pink original in inpatient record 0 0 2 2 
Copy of MOLST in record 1 0 1 1 
**Note:  A change was effected in documentation of LOT in hospitalist’s History & Physical, Daily Progress Notes, and Discharge 
Summary, to include standing required field for LOT with drop-down menu for:  Full Code; DNR; DNI.  
HIGHLIGHTS OF CHART REVIEW: 
Pink original form was in the chart in a number of cases; unknown if patient took a copy with them to discharge destination or 
not.  (Difficult part of paperwork process with no tracking of copies.) 
Percentage of patients with LOT documented while in the hospital increased during the demonstration program. Not sure if 
that is due to improved documentation by hospitalists through a standardized drop-down menu on all of their electronic 
documentation tools, or instead due to increased conversations about EOL/LOT in general producing an improvement in 
number of conversations. 
 
Key Findings:  
• The acute care setting can be an appropriate place to discuss MOLST, especially with those patients who are 
already in a cycle of care transitions between nursing homes, rehabilitation, acute care, etc., and may not 
return to their primary care physicians. 
• All clinicians in the acute care setting should regard goals of care discussions with patients near the end of life 
(which may result in signing the MOLST form) as a part of their role.  This will require not only a cultural 
change in some medical practices, but also behavioral change among some individual clinicians. 
• MOLST needs an administrative “home” and at least one clinical champion/coordinator within the institution.  
Personal attention and presence on the clinical floors (e.g. to carry out strategies as simple as placing blank 
MOLST forms in the charts of patients suitable for MOLST) was the best way to move MOLST from concept to 
implementation. 
• Health providers need expert coaching when it comes to MOLST and other aspects of end-of-life care.  Most 
clinicians have some degree of understanding of these complex topics, but even those with a high level of 
                                                          
23 St. Vincent Hospital joined the program later than the other demonstration sites.  Due to the departure of its 
lead “MOLST champion,” the MOLST process and form did not go into use at St. Vincent Hospital during the 
demonstration. 
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expertise have something to learn from this new process, especially in regards to the process of medical 
decision-making, advance care planning, and the differences between advance directives and MOLST. 
• Policy and procedure development and approval takes much more time than may be anticipated.  
• To ensure that MOLST information and expertise are readily available throughout the institution, a train-the-
trainers strategy would be most effective, rather than relying on one or two people to support the ongoing 
training and coaching needs of a large and varied staff. 
• It is more effective to start small with the initial implementation of MOLST in a large, complex acute care site – 
with “ones” (e.g. one department, one unit, one floor, one hospitalist). 
• The most challenging place to implement MOLST is in the Emergency Department; too much “chaos;” too 
much going on. 
• The Emergency Department clinicians anticipate that the MOLST form is at high risk of being lost during 
transitions between care settings, and encourages the use of electronic versions as much as possible. 
• The Emergency Department physicians thought that the bedside nurse was the best person to be aware of the 
presence of a MOLST form and to take responsibility for communicating its existence to the Emergency 
Department team. 
• Emergency Department clinicians anticipate using only the front of the form for most encounters in their 
clinical setting due to their time-limited role in patient care. 
• Emergency Department clinicians report that they get a call from most EMTs “in the field” prior to honoring 
the current CC/DNR form encountered in the home setting and expect that a similar call will take place for 
encounters with the MOLST form. 
• Emergency Department clinicians recommend making a copy of a MOLST form prior to sending it to the ED, in 
case the form is not returned to the referring facility or patient. 
• Emergency Department clinicians indicate that there is currently no standardized process for asking about the 
existence of a CC/DNR form, MOLST form or other statements of patient preference in the emergency policies 
and procedures. 
 
Primary Managed Care Geriatric Home Visiting Program 
Fallon Clinic Geriatric Managed Care Home Run Program 
Notes:  150 patients at one time; fragile medical condition; most 65+ 
 
“Snapshot” of MOLST utilization in Fallon Home Run Program - An in-depth review by the Fallon Clinic 
Research Department in late November 2010 of the electronic medical records and paper charts of patients 
enrolled in the Home Run Program during the MOLST demonstration provided the following snapshot. 
 
Overview  
Patient charts reviewed 260 
Ages of the patients 61 -100 years old 
Patients with CC/DNR verification forms 148/260 
MOLST discussions  
Patient who discussed MOLST with clinician 115/260 
Family members who discussed MOLST with clinician  37/260 
Average discussions per patient before signing MOLST  4 
MOLST form patient utilization  
Patients who signed a MOLST form 58/115 
MOLST forms signed by the patient 47/58 
MOLST forms signed by the health care agent 6/58 
Unclear (to reviewer) if it was patient or agent that signed 5/58 
Patients who signed MOLST who also had CC/DNR 53/58 
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MOLST forms with instructions in Section A 51/53 
MOLST forms with instructions in Section B 51/53 
MOLST forms with instructions in Section C 50/53 
MOLST forms with instructions in Section F 
• Section F instructions about respiratory support 
• Section F instructions about dialysis 
• Section F instructions about artificial nutrition 
• Section F instructions about artificial hydration 
• Valid Section F (required information provided) 
52/53 
51/52 
52/52 
52/52 
52/52 
52/52 
MOLST forms with optional health care agent info in Section G  14/58 *  
MOLST forms were honored 8 known (these patients also had CC/DNR) 
MOLST forms voided 2 
MOLST forms with valid medical orders  
Note: Both Sections D and E must be correctly completed for 
valid orders in Sections A – C  
32/58 
32 forms completed correctly in Section D 
(patient info); 43 forms completed correctly in 
Section E (clinician info) 
* Note: 130 of the 260 charts reviewed contained health care agent information; the NPs opined that many 
patients incorrectly think that if they have filled out a power of attorney, that the power of attorney covers 
everything. 
 
Key Findings: 
• Several unique characteristics of the Home Run program lent to its value and contribution as a MOLST 
demonstration site:  it was the only “primary managed care” demonstration site; its Home Run program 
features monthly home visits conducted (in collaboration with VNA Care Hospice – another MOLST 
demonstration site) by nurse practitioners capable of discussing goals of care with patients and authorized to 
sign MOLST forms with them24
• The Home Run program established the following protocol for utilizing MOLST with patients:  1)discuss 
existing limitations of treatment and/or related patient preferences and goals of care; 2)introduce basic 
concept of MOLST and provide MOLST educational materials; 3) inform patient/family about what to do next if 
they are interested in MOLST (who to call with questions, process of necessary discussion with the nurse 
practitioner or other physician); 4) ensure patient/family understanding that the MOLST form is 
; nearly all of the patients enrolled in Home Run could be suitable for MOLST; 
and Fallon’s electronic medical record/data base allowed for the tracking of MOLST experiences per individual 
patients. 
not
• Most patients offered MOLST used it, even though they had CC/DNR already; furthermore they utilized all 
sections of the form to express more preferences than accommodated by the CC/DNR. 
 to be first 
filled out without the clinician and then given to the nurse/doctor for signature; 5) inform patient’s primary 
provider when MOLST information is given to prepare primary providers for next steps; 6) discuss and sign 
MOLST orders with patients as appropriate; 7) copy MOLST forms for entry in patients’ medical record. 
• The majority of MOLST forms were used to refuse treatment.  MOLST forms were not routinely offered for use 
by patients who wanted full treatment. 
• An average of four visits preceded the patient signing the MOLST form.  “Some (patients) are ready right 
away” but often the nurse practitioners (NPs) chose to leave the MOLST materials for the patients to consider 
with their families, then continued the MOLST discussions and started filling out the form at the second visit.   
• The average total amount of time taken to sign the MOLST from start to finish was one hour. 
                                                          
24 Most home visiting programs employ nursing aids, LPNs, RNs or social workers for visits to patients’ homes. 
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• According to the NPs, the most common obstacle preventing patients who wanted a MOLST from actually 
signing one was their adult children, who don’t want their parents signing anything and/or don’t want to let 
go.  
• Another barrier (to all advance care planning) is that patients “are afraid that if they sign a MOLST they won’t 
get cared for properly.”  
• A lot of time was spent explaining the medical treatments with patients and families who often do not 
understand them, especially CPR.  NPs said they seem to think the hospital is some magical place and that 
after they receive these treatments they will come back in the same (or healthier) state as before.   
• Using the MOLST form led to more thorough conversations between the NPs and patients and families 
(especially about life-sustaining treatments beyond resuscitation). 
• NPs said, “MOLST is a great thing.  It should be all over the state.  A public education campaign about all of 
these (EOL) issues is very important, especially targeting the adult children/caregivers of elderly.”  
 
Emergency Medical Services 
UMass Memorial Health Care EMS, Central Massachusetts EMS, some local first responders  
Notes: Region Two EMTs were required to honor MOLST forms; EMTs statewide were authorized but not 
required to honor MOLST. 
Key Findings: 
 
• EMTs immediately understand the MOLST form (in the context of their experience with Comfort 
Care form). 
• Most EMTs that received training considered the MOLST form an improvement from the Comfort 
Care form. 
• EMTs like the simplicity of page one of the MOLST form, tailored for ease of pre-hospital use. 
• If they participated in training, EMTs understood that MOLST does not change their current 
protocols. 
• They expressed concern that physicians would not fill in the form correctly for it to be valid. 
• They expressed concern about the portability of the form. 
• They thought a registry would be helpful. 
• EMTs requested that patients, families and health providers all receive better information about 
EMTs’ role, because “as with Comfort Care the biggest issue will be educating the public and the 
medical community (healthcare providers at hospitals, nursing homes and assisted living facilities) so 
everyone understands the proper use of MOLST in conjunction with the pre-hospital community.” 
• They expressed nearly unanimous concern that Massachusetts EMTs are currently or might soon be 
required to honor the MOLST form without receiving any information or training about MOLST. 
“There should be a defined implementation date with ample time to train all the necessary agencies 
that may be involved in patient care. (Director of a hospital-based life support service) 
• EMTs asked that MOLST training be required for re-certification if MOLST goes statewide, because 
“the MOLST form looks interesting but full of potential for misinterpretation and confusion especially 
to newer pre-hospital providers.”  
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Attachment C 
Massachusetts Department of Public Health Circular Letter:   
DHCQ 10-02-529 
 
 
 
 
The Commonwealth of Massachusetts  
Executive Office of Health and Human Services  
Department of Public Health  
250 Washington Street, Boston, MA 02108-4619  
   
Circular Letter:  DHCQ 10-02-529  
  
TO:   Acute Care Hospitals Chief Executive Officers  
 Emergency Department Directors and Chief Nursing Officers    
 Long Term Care Facility Administrators, Medical Directors and Directors of Nursing   
 Licensed Ambulance Services  
 EMS Accredited Training Institutions  
 EMS Regions I-V  
 EMCAB  
 
FROM:  John Auerbach, Commissioner, Department of Public Health 
 Alice Bonner, Director, Bureau of Health Care Safety and Quality  
 Stancel Riley, Executive Director, Board of Registration in Medicine  
 Jean Pontikas, Director, Division of Health Profession Licensure     
 Rula Harb, Executive Director, Board of Registration in Nursing  
 Sally Graham, Executive Director, Board of Registration of Physician Assistants  
 Abdullah Rehayem, Director, Office of Emergency Medical Services  
  
DATE: February 4, 2010  
  
 
 
Introduction:  
This is to notify you of a demonstration program to implement a MOLST (Medical 
Orders for Life-Sustaining Treatment) process and form in select Worcester area health 
care settings, starting in early spring, 2010. 
In its April 2008 Annual Report, the Massachusetts Heath Care Quality and Cost 
Council (“MHCQCC”) recommended that Massachusetts establish a pilot program to 
improve communication across health care settings regarding patient preferences about 
end of life treatments.  In its report, the MHCQCC found widespread evidence that many 
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patients nearing the end of life lacked awareness of treatment options and had not 
discussed their preferences for treatment and care with their clinicians.  Further, the 
MHCQCC noted that even when such discussions did occur and the clinician documented 
patient treatment choices in the patient’s medical chart, the medical system lacked a 
mechanism to ensure that such documentation would be communicated and honored by 
clinicians across health care settings.  Following this recommendation, in August, 2008, the 
Legislature enacted Chapter 305, Section 43 of the Acts of 2008, which, in part, requires 
that the Executive Office of Health and Human Services (“EOHHS”) establish a pilot 
program to test the implementation of a POLST Paradigm program “to assist individuals in 
communicating end-of-life care directives across care settings in a least 1 region of the 
commonwealth.” 
Although the demonstration program will be implemented in select health care 
facilities located in the Worcester area, the Department of Public Health (“DPH”) is 
circulating this announcement state-wide to provide clinicians with background information 
about the MOLST process, form, and the Massachusetts Medical Orders for Life-Sustaining 
Treatment demonstration program (“MA MOLST program”).  
   
 
MA MOLST Demonstration Program: 
The MA MOLST Program is being coordinated and managed by the UMass Medical 
School-Commonwealth Medicine Center for Health Policy and Research, with oversight 
from a 30-member broad-based Steering Committee, chaired by representatives from DPH 
and the Office of Elder Affairs. The goals of the MA MOLST Program are:  1) to facilitate 
discussions between clinicians and their patients nearing the end of life about treatment 
options and preferences for care; and 2) to provide clinicians and their patients with a 
mechanism for translating these preferences into portable signed medical orders (through 
the use of a MOLST form) which travel with the patient and can be honored across health 
care settings. 
 
Modeled on a nation-wide initiative known as the POLST (Physician Orders for Life-
Sustaining Treatment) Paradigm Program1  the MA MOLST Program is similar to programs 
currently in effect in all or parts of twenty (20) states within this country.  Such programs are 
grounded on well-established legal and ethical principles involving patient self-determination 
and a patient’s right to accept or refuse medically-indicated treatments, including life-
sustaining treatments. MOLST is intended for voluntary use by patients nearing the end of 
life due to serious advancing medical conditions, including but not limited to life-threatening 
diseases, chronic progressive diseases, life-threatening injuries or medical frailty.  Clinicians 
can collaborate with the patient, health care agent or guardian
 
to complete a concise 
document--the MOLST form--that reflects the patient’s preferences for medically-indicated 
treatments.  When completed and signed by the patient and attending physician, nurse 
practitioner or physician assistant, the patient’s MOLST form constitutes an actionable 
medical order that can be recognized and honored across treatment settings. 
1See www.polst.org for more information. 
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Attached is a sample form entitled Massachusetts Medical Orders for Life-Sustaining 
Treatment (MOLST) that will be used in the MA MOLST demonstration program.  The front 
side of the form is designed to be easily accessible to all health professionals and 
particularly useful to EMS personnel in emergency settings. The form is similar to the form 
currently honored by EMS personnel under the Comfort Care/Do Not Resuscitate 
(“CC/DNR”) Verification protocol established by DPH’s Office of Emergency Medical 
Services (“OEMS”).  Please note that because the MOLST processes and form are not 
being implemented state-wide at this time, the CC/DNR Verification protocol will remain 
valid in the MOLST demonstration area and throughout the Commonwealth.  
The MOLST form contains instructions relating to three treatment options: A) 
cardiopulmonary resuscitation in the case of cardiac or respiratory arrest (either “do not 
resuscitate” or “attempt resuscitation”); B) intubation and ventilation (“do not intubate and/or 
ventilate” or “intubate and/or ventilate” and C) transfer to hospital (“do not transfer to 
hospital, unless needed for comfort” and “transfer to hospital”) and requires the signatures 
of both the clinician and the patient or health care agent/guardian.  The back side of the 
MOLST form contains the patient’s preferences about other medically-indicated treatments 
that may be offered in a clinical setting, including respiratory support, dialysis, artificial 
nutrition, artificial hydration and any other preferences the patient chooses to document. 
The DPH, the Boards of Registration in Nursing and Physician Assistants and the 
MA Board of Registration in Medicine support the use of the MOLST process and form as 
an appropriate way to meet the standard of care for communicating patient preferences 
regarding life-sustaining treatment options. Further, given the intent of the MOLST 
demonstration project, DPH, the Boards of Registration in Nursing and Physician Assistants 
and the MA Board of Registration in Medicine encourage all health professionals to honor 
valid MOLST forms as bona fide medical orders. 
 
 
Implementation Plan:  
The MA MOLST demonstration program will be implemented in the following health 
care settings:  UMass Memorial Medical Center, St. Vincent Hospital; Shrewsbury Nursing 
and Rehabilitation Center; Notre Dame Long Term Care Center and Hospice; Jewish 
Healthcare Center and Hospice; UMass Memorial Home Health & Hospice; VNA Care 
Hospice; Fallon Clinic, and EMS services in Worcester County.  It is expected that the 
actual MOLST process and form will go into use within the implementation sites by late 
March, 2010. 
In order to fully prepare for this activation, the MA MOLST Program, together with 
DPH staff and other EOHHS representatives are proceeding with the following steps:  
  
• Training MOLST signatories (physicians, nurse practitioners and physician 
assistants) and other health professionals (nurses, EMTs, social workers, and other 
staff)  in the demonstration sites about the MOLST process and form;   
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• Conducting outreach and education to other health providers and stakeholders in the 
greater Worcester area that may encounter patients with MOLST forms;  
• Conducting  outreach and education to inform potential consumers (patients, their 
families and caregivers)  in the demonstration sites and Worcester area about the 
MOLST program; 
• Convening a MOLST launch event for Worcester-area health professionals, 
consumers, and other interested stakeholders, on February 10 in Worcester;  
• Posting MOLST information, resources and materials to a MOLST website 
(at:  www.molst-ma.org) to be accessible by March 2010;    
• Finalizing the design of the evaluation and quality improvement measures to be 
utilized to test the efficacy of the demonstration program and to make 
recommendations for a state-wide expansion of the MOLST process and form;   
• Submitting a report to the Legislature regarding the findings of this demonstration 
program and recommendations for state-wide implementation of MOLST by 
December 2010. 
 
Conclusion:  
  
In closing, we want to acknowledge the tremendous amount of work that has already 
been accomplished to develop a MA MOLST demonstration program that is tailored to 
patient needs and the Massachusetts health care system.  We would like to thank all those 
who have participated in this effort.  We also would like to extend our appreciation to the 
demonstration sites that have agreed to implement the MOLST process and form with their 
patients.  We thank you for your participation and for all of your work to further this 
important patient-centered care initiative.  
  
  
ATTACHMENTS:  
  
MA MOLST FORM-SAMPLE  
  
MA MOLST STEERING COMMIITTEE MEMBERSHIP 
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Attachment D 
MA MOLST Form – Demonstration Version 
 
 
 
37 
38 
Attachment E 
 
Frequently Asked Questions about the Massachusetts MOLST Form 
The proposed Massachusetts MOLST form was developed based on research concerning the 
POLST/MOLST experience in other states, dozens of key informant interviews before the demonstration 
was launched, and comments solicited during the course of the demonstration.25
 
 The following table 
sets forth some of the comments/concerns that were expressed as well as the responses reflected on 
the recommended  Massachusetts MOLST form.  
IMPORTANT NOTE: MOLST does not eliminate the need to appoint a health care agent.  
All Massachusetts residents over age 18 should sign a health care proxy form to appoint a health care 
agent, and have conversations with their health care agent about their preferences should they lose the 
capacity to make and communicate their own health care decisions.  
 
 Question Response 
What is a MOLST form and who should consider using one? 
1 What is a MOLST form? A MOLST form is one possible outcome of planning 
for care at the end of life.   MOLST serves as a portable 
form that documents the discussions about life-
sustaining treatments so that clinicians can build on 
earlier conversations. 
2 Should everyone have a MOLST form? No. MOLST is most suitable for patients with a serious 
advancing medical condition, including, but not limited 
to: life threatening disease, chronic progressive 
disease, acute injury, or medical frailty. 
Purpose and Use of MOLST 
4 Does MOLST require individuals (or their agents) to 
decline treatment? 
No. MOLST can be used either to limit or to allow 
specific types of medically-indicated treatments.   
5 Can these difficult medical issues be discussed and 
decided in one conversation? 
Multiple conversations over time are the norm. The 
form allows for indicating that the patient is currently 
undecided about a certain intervention or that the 
intervention was not discussed. 
6 Will the MOLST form be used as a script for patient 
conversations? 
It should not. Clinicians need to communicate with 
patients first about their medical condition, prognosis, 
the potential burdens and benefits of any 
recommended treatments, as well as the patient’s 
values and goals of care before introducing a MOLST 
form.  
7 Why are the choices on the MOLST form limited?   A MOLST form must be usable by emergency 
                                                          
25 Interviews were conducted with Massachusetts clinicians with training and experience in geriatrics, palliative 
care, critical care, emergency medicine, pulmonary medicine, hospice care, home health care, as well as social 
workers, hospital and nursing home administrators, first responders, lawyers, and staff at the Massachusetts 
Department of Public Health (DPH), the DPH Office of Emergency Medical Services (DPH OEMS), the DPH Office of 
Long-Term Care, and the Boards of Registration. Consumer focus groups were held and follow-up comments were 
received from people who had experience using the form.  
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responders who do not have time to interpret complex 
or ambiguous instructions. MOLST is best understood 
as an enhanced CC/DNR Verification Protocol form 
since it includes more treatment options, may be used 
to request or refuse treatment, and is honored by all 
health professionals.   
8 Why isn’t the phrase “Comfort Measures” used?  Comfort Measures means different things to different 
clinicians at different institutions. The instructions 
state “Every patient should receive full attention to 
comfort.” 
Sections A, B and C (Page 1) 
9 Many other states use forms that give patients a 
choice between three different levels of treatment:  
“Full Treatment”, “Limited Intervention,” or “Comfort 
Measures Only.” Why aren’t those choices included 
on the MOLST form? 
MOLST encourages the development of an 
individualized, patient-centered plan of care rather 
than defining limited categories of care to meet every 
patient’s needs.   
10 Do the orders conflict if someone opts for CPR under 
Section A but doesn’t want Intubation and Artificial 
Ventilation under Section B? 
Sections A and B represent responses in different 
clinical situations. Section A is the response to cardiac 
or respiratory arrest while B is the response to 
respiratory distress. Anyone who requests CPR in 
Section A will get all the treatments that are part of 
that procedure, including intubation. Clinicians should 
provide education to patients about each intervention 
during discussions about MOLST.  
Section F  (Page 2) 
11 Why were these specific choices included?  The form must be simple enough to be usable without 
trying to address every possible choice. MOLST 
includes common life-sustaining interventions needed 
as many chronic illnesses progress, but individual 
preferences can be added in the section called ‘Other 
Treatment Preferences’ within Section F. 
12 Why aren’t “antibiotics” included as a treatment 
preference? 
Experience in other states indicates that including 
antibiotics has not been helpful. Use of antibiotics is 
one of a number of treatment options that may be 
used for curative or palliative purposes and whether its 
use will be appropriate is difficult to predict in 
advance.  Though it is not specifically listed, it can be 
included in “other treatment preferences” under 
Section F, if appropriate. 
13 Why doesn’t the form indicate forms of artificial 
nutrition?  
It is the clinician’s role to fully explain any appropriate 
types of medically-indicated treatment to the patient 
when needed; MOLST is intended to express whether 
or not the patient wants that type of support, if 
needed.  Specific forms of artificial nutrition can be 
included in “other treatment preferences” under 
Section F, if appropriate. 
14 How is “short-term” defined? It seems vague. “Short-term” isn’t defined. The time frame should be 
determined by the clinician and patient based on each 
situation and patient. MOLST gives the patient a 
chance to indicate whether or not they agree to the 
treatment on a long-term/indefinite basis or for a 
“time-limited trial” with specific treatment goals.  
Sections D and E and Sections G and H - Signature Provisions  
15 How are “guardian” and “health care agent” The definitions used for the Comfort Care/Do Not 
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defined? Resuscitate Verification Protocol apply. The guardian 
must be court appointed and the health care agent 
must be designated on a valid health care proxy. 
16 Why are both the clinician and the patient or patient 
representative required to sign the first page?  In 
other words, why include Section D and Section E? 
The clinician’s signature is required to create a medical 
order. The patient or patient representative signature 
indicates that the MOLST is consistent with the 
patient’s goals of care as discussed with the clinician 
signer. Sections A, B and C are valid orders ONLY if 
both Sections D and E are completed. 
17 Why are both the clinician and the patient or patient 
representative required to sign the second page?  In 
other words, why include Section G and Section H? 
The clinician signature assures that the preferences 
expressed were discussed with the clinician, adds 
weight or significance to the preferences, and could 
help deter unauthorized people from signing. The 
patient or patient representative signature indicates 
that the Section F preferences are consistent with the 
patient’s goals of care as discussed with the clinician 
who signed Section H. Section F is valid ONLY if both 
Sections G and H are completed. 
18 What if sections D and E are signed but sections G 
and H are not signed? 
Then Sections A, B and C would be valid orders but  
Section F preferences would not be valid.  
Additional  General Issues 
19 What if a section of the MOLST form is not 
completed? 
If a section has not been completed there is no 
limitation on the treatment indicated in that section. 
20 If the intent is to review MOLST periodically, why not 
specify a time frame for review or require an 
expiration date? 
The need to review and modify the form periodically 
will depend on each patient’s circumstances. 
Consistent with the CC/DNR Verification Protocol form, 
MOLST includes an optional expiration date at the 
bottom of page one allowing for a periodic review 
requirement to be developed by individual 
institutions/agencies, if appropriate.  
21 Will there be a problem differentiating an outdated 
MOLST form once revisions have been made from the 
new MOLST form created?  In other words, how will 
we know if a MOLST form is the most current 
version? 
Use of original MOLST forms is encouraged; however, 
experience with the CC/DNR Verification Protocol form 
indicated that it was unduly limiting to require use of 
original forms only.  As a result, photocopy, fax or 
electronic copies of MOLST are acceptable. Care needs 
to be taken to account for old copies of the form to be 
sure they are voided. This issue is covered in 
instructions for clinicians and patients/families. 
22 What happens to the current CC/DNR Verification 
Protocol form and how does the MOLST form 
compare to the CC/DNR Verification protocol form?  
The CC/DNR Verification Protocol form remains valid in 
Massachusetts. EMS personnel are authorized to honor 
either a MOLST form or a CC/DNR Verification form. It 
is possible that MOLST could eventually replace the 
CC/DNR Verification form after a successful statewide 
MOLST rollout.  
23 Where should individuals display their MOLST forms 
to assure that emergency responders will find them 
in a timely way? 
Emergency responders are trained to ask if there is a 
MOLST form and then, in homes, to check the 
refrigerator door and bedside areas. Original MOLST 
forms are bright pink. Non-pink copies are also valid 
but may be harder to locate and recognize.  Patients 
are encouraged to carry their MOLST form (or a copy) 
when they travel outside of their homes. 
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Attachment F 
MOLST Education and Outreach Activities through June 201026
ACUTE CARE SITES 
 
Dates Duration Locations Participants by Profession 
 Numbers 
reached  
September 
2009 - 
June 2010    
 
 
       
Range: 10 - 
90 minutes 
 
Average 37 
minutes 
 
Mostly UMMMC, Saint Vincent (2), 
Barre Family Medical Ctr.,  Fairlawn 
(1); Great Brook Valley (1) 
 
  
Chiefs, ethics, physicians, NPs, PAs, 
nurses, residents, social workers, care 
coordinators, clergy, patient care services, 
lawyers, medical interpreters, pharmacists 
 
 
Range: 8 - 60;  
Average 23                      
 
Total 562 
 
 
EMTs and FIRST RESPONDERS 
Date Duration Locations Participants by Profession 
 
Numbers reached 
February - 
November 
2010  
60 min OEMS regions throughout MA; 
fire/police in Shrewsbury, 
Northborough, Sterling, others  
EMTs, fire fighters, police, administrators EMTs certified  
(per OEMS): 
 
Total 700+ 
NURSING HOMES, HOME HEALTH, HOSPICE and Fallon Clinic 
Date Duration Location Participants by Profession Numbers reached 
February - 
June 2010 
Range:  15 - 
90 minutes 
 
Average 32 
minutes 
Shrewsbury Nursing & Rehab, VNA 
Care Hospice; Jewish Health Care, 
Notre Dame Long Term Care 
Center, UMass Memorial Home 
Care & Hospice; Fallon Clinic 
Administrators, physicians, nurses, social 
workers, resident council members, 
physical therapists and assistants, 
occupational therapists and assistants, 
chaplains, volunteers,  
Range: 5 - 50        
Average 21            
 
Total 535 
 
 
 
 
COMMUNITY GROUPS and ORGANIZATIONS 
Date Duration Location Participants by Profession Numbers reached 
June 2009 
- June 
2010 
Range: 20 -
90 minutes  
 
Average 52 
minutes 
Various, mostly Central 
Massachusetts and Boston 
Health professionals, policy-makers, 
health care administrators, health plan 
administrators, state expert panel, state 
officials, lawyers, judges, consumer 
advocates                                                                                            
Range: 2 - 150           
Average 21     
       
Total 479 
 
                                                          
26 With the exception of EMT training, these data were tracked until June 2010.  Training and outreach continued untracked throughout 
December 2010, so numbers of participants reached in all groups and settings are higher than those indicated here. 
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Attachment G 
MOLST Demonstration Materials Developed and Disseminated 
 
Concurrent with MOLST form development, the Steering Committee and work groups were 
engaged in drafting and testing essential MOLST educational materials for patients and their 
caregivers, clinicians and other health professionals.  This process, involving significant 
engagement of and input from both health professionals and community members resulted in a 
wide range of resources for multiple audiences as shown below. 
Resource/Material Approximate 
number of 
hard copies 
disseminated 
Patients, 
Families, 
Caregivers 
Clinicians and 
other health 
professionals 
General public, 
professionals 
and groups 
MOLST sample form (translated into 
Spanish, Portuguese, and Vietnamese)  
2300 X X X 
Patient and family MOLST brochure 2200 X   
Understanding the MOLST form 2-page 
guide (translated into Spanish and 
Vietnamese) 
2000 X   
13-minute original informational 
MOLST video – hard copies and 
viewable on MOLST website 
110 discs X X X 
Frequently Asked Questions of patients 
and families (translated into Spanish 
and Vietnamese) 
1850 X   
Clinical guidance booklet for using 
MOLST 
350  X  
MOLST training module for  
clinicians/signers 
TBD  X  
MOLST training module for health 
professionals 
TBD  X  
MOLST training module for EMTs/First 
Responders 
TBD  X  
Frequently Asked Questions – 
Clinicians 
1050  X  
Frequently Asked Questions – health 
professionals 
1350  X  
Frequently Asked Questions–
EMTs/First Responders 
900  X  
Frequently Asked Questions – Assisted 
Living Residences 
150  X  
Frequently Asked Questions – Lawyers 60   X 
Differences - MOLST and Health Care 
Proxy Form 
250 X X X 
Glossary of end-of-life terms 1750 X X X 
MOLST website with all materials and 
other resources  Mar 1 – Dec 31, 2010 
www.molst-ma.org 
 
# visits: 2921 
 
X X X 
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Attachment H 
 Glossary of Terms Related To End-of-Life Planning and Care 
Advance care planning (ACP
 
) is an ongoing process of discussing and clarifying the current state of a person’s 
goals, values and preferences for future medical care.  The discussion often, but not always, leads to the signing of 
documents known as advance directives.  A health care proxy is the only advance directive authorized by 
Massachusetts statute.   
Advance directive (AD)
 
 is a general term referring to a written document for future medical care in the event that a 
person loses capacity to make health care decisions (i.e. becomes “incapacitated.”).  It sometimes results from the 
process known as advance care planning.  A health care proxy or a living will is considered to be an advance 
directive.   
Artificial hydration and nutrition (AHN)
 
 is a medical treatment that supplements or replaces ordinary eating and 
drinking by giving a chemically balanced mix of nutrients and/or fluids through a tube placed directly into the 
digestive tract (enteral); or through a tube directly into a vein (parenteral). 
Cardio-pulmonary resuscitation (CPR)
 
 is a set of medical procedures that attempt to restart the heartbeat and 
breathing of a person who has no heartbeat and has stopped breathing. Such procedures may include pressing on the 
chest to mimic the heart’s functions and cause blood to circulate; insertion of an airway into the mouth and throat, or 
insertion of a tube into the windpipe; artificial ventilation such as mouth-to-mouth or other mechanically assisted 
breathing; the use of drugs to stimulate the heart; and/or electric shock (defibrillation) to stimulate the heart. CPR 
can be life-saving in certain cases for otherwise healthy people but is much less effective when a person has a 
serious chronic illness. 
Comfort Care/Do Not Resuscitate Verification protocol (CC/DNR)
 
 is followed by emergency medical service 
(EMS) personnel when encountering an authorized CC/DNR Verification Form outside of a hospital setting.  The 
CC/DNR protocol directs that a patient in respiratory or cardiac distress be made as comfortable as possible, but that 
no resuscitative measures be attempted.  
Decision-making capacity
 
 refers to the ability to make and communicate meaningful decisions based upon an 
understanding of the relevant information about options and consideration of the risks, benefits, and consequences of 
the decision. The ability to understand other unrelated concepts is not relevant.  Capacity can vary according to the 
task:  it may be possible for an individual to appoint a health care agent, for example, yet not make a decision about 
a medical procedure. Capacity should be assessed routinely and is not the same as competence, which is a legal 
determination made in court. In Massachusetts a physician must make the determination of a patient’s lack of 
capacity in writing before a health care proxy can be put into effect. 
Dialysis
 
 is the process of filtering the blood through a machine via two small tubes inserted into the body in order to 
remove waste products from the body in the way that the kidneys normally do.  Dialysis can be done temporarily in 
order to allow the kidneys time to heal or it can be done on a longer-term basis in order to prolong life. 
Do Not Hospitalize orders (DNH)
 
 are medical orders signed by a physician that instruct health care providers not 
to transfer a patient from a setting such as a nursing facility (or one’s home) to the hospital unless needed for 
comfort. 
Do Not Intubate orders (DNI) are medical orders signed by a physician that instruct health care providers not to 
attempt intubation or artificial ventilation in the event of respiratory distress. 
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Do Not Resuscitate orders (DNR) are medical orders signed by a physician that instruct health care providers not 
to attempt cardio-pulmonary resuscitation (CPR) in the event of cardiac and respiratory arrest. 
 
Durable Power of Attorney for Health Care is a term used in some states for a health care proxy.  (See definition 
below.) 
 
Guardian is a court-appointed individual granted authority to make certain decisions regarding the rights of a 
person with a clinically diagnosed condition that results in an inability to meet essential requirements for physical 
health, safety or self-care.  In Massachusetts not every guardian has authority to make health care decisions.  If a 
health care proxy is in effect, a healthcare decision of the agent takes precedence over that of the guardian (absent an 
order of the court to the contrary). Further, guardians who do have authority to make health care decisions may be 
subject to limitations on their authority to make decisions regarding life-sustaining treatments. 
 
Health care agent is a trusted person, officially appointed, who speaks on behalf of a person 18 years of age or 
older who is unable to make or communicate health care decisions. In Massachusetts this person is appointed in 
advance via a health care proxy. The agent is called upon only if the doctor determines in writing that a patient lacks 
capacity to make health care decisions.  Unless otherwise limited by the person, the agent has all the rights that the 
patient has with regard to medical decision-making, including the rights to refuse treatment, to agree to treatment, or 
to have treatment withdrawn. Decisions should first be made based on the patient’s stated wishes, if known; or if 
unknown, an interpretation of what the patient would have wanted; or finally, an assessment of the patient’s best 
interest. 
 
Health care proxy (HCP) is a document in which a person appoints a health care agent to make future medical 
decisions in the event that the person becomes incapacitated.  This may be an outcome of the advance care planning 
process and is expressly authorized in Massachusetts by statute (MGL 201D). 
 
Hospice is a philosophy of holistic end of life care and a program model for delivering comprehensive palliative 
care to persons who are in the final stages of terminal illness and their loved ones in the home or a home-like setting. 
Hospice provides palliative care in the last months of life.  It involves a team-oriented approach that is tailored to the 
specific physical, psycho-social and spiritual needs of the person and includes support to the family during the dying 
process.  Hospice also provides bereavement support after death occurs.  
 
Life-sustaining treatment refers to medical procedures such as cardio-pulmonary resuscitation, artificial hydration 
and nutrition, and other medical treatments intended to prolong life by supporting an essential function of the body 
in order to keep a person alive when the body is not able to function on its own. 
 
Living will (LW) is a document in which a person specifies future medical treatments in the event of incapacity, 
usually at end of life or if one becomes permanently unconscious, in a persistent vegetative state or “beyond 
reasonable hope of recovery.” Since there is no statute in Massachusetts that expressly authorizes living wills they 
are not considered to have legal authority.  They may, however, be used as evidence of a person’s wishes.  
 
Medical (or Physician’s) Orders for Life-Sustaining Treatment (MOLST /POLST)  is a document intended for 
seriously ill patients that stipulates wishes for life-sustaining treatment based on the patient’s current condition. A 
MOLST form becomes effective immediately upon signing and is not dependent upon a person’s loss of capacity.  It 
does not take the place of a health care proxy.  Consideration of MOLST may be an outcome of the advance care 
planning process.  
 
Palliative care is a comprehensive approach to treating serious illness that focuses on the physical, psycho-social 
and spiritual needs of the patient.  The goal of palliative care is to prevent and relieve suffering and to support the 
best quality of life for patients and their families through such interventions as managing pain and other 
uncomfortable symptoms, assisting with difficult decision-making, and providing support, regardless of whether or 
not a patient chooses to continue curative, aggressive medical treatment. 
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